Are histopathological benchmarks included for clinical correlation?

Yes. Synovial inflammation scoring (H&E, Safranin O) and CNS demyelination indices (LFB/PAS) adhere to MIATA/ARRIVE guidelines, with pathologist-verified severity scales.

How are comorbidities (e.g., IBD dysbiosis) controlled?

Defined microbiota diets, cohousing, and antibiotic regimens isolate autoimmune mechanisms. 16s rRNA sequencing and lamina propria profiling distinguish primary pathology.

Do models replicate human immune responses for IND submissions?

Yes. HLA-transgenic models (HLA-DR3/4) and PBMC/human cytokine systems mimic human responses, pre-validated for MHC-II–peptide interactions and checkpoint inhibitor studies.

How do you ensure long-term model stability (e.g., NOD mice)?

≥10 generations of backcrossing, SNP monitoring, and cryopreservation minimize drift. Phenotypic checkpoints (insulitis scoring, autoantibody titers) ensure consistency.

Can you engineer tissue-specific gene edits (e.g., Tlr2 KO in T cells)?

Yes. Cre-loxP inducible systems and tissue-specific promoters (CD4, CD11c) enable precise targeting. Dual-gene edits (Il23r/Stat3 KO) dissect polygenic interactions.

How do your models replicate human autoimmune biomarkers (e.g., lupus)?

Validated using disease-specific biomarkers: Th17/Treg ratios (flow cytometry), serum autoantibodies (anti-dsDNA), and cytokine panels (IL-17, TNF-α). Immune profiling (CD4+ T cells, B220+ B cells) aligns with human pathologies like SLE or RA.

Custom Autoimmune Disease Models for High-Quality Research

Autoimmune Disease Models

Reduce technical risk with rigorously validated, publication-ready models (e.g., BSA+CCL4+LPS-induced IgA Nephropathy) and TurboKnockout®-engineered efficiency (60% faster gene editing). Ethically optimized designs align with 3R principles to streamline IND-enabling studies.

Clinical Predictability

Achieve 85% translational concordance with IND-enabling histopathology and cytokine data.

Target Validation

Uncover novel pathways using gene-engineered models (e.g., TLR2 KO) with tissue-specific promoters.

Precision Drug Profiling

Test candidate efficacy and immune safety in models pre-validated with human biomarkers (e.g., Th17/Treg ratios).

Overview

Product

FAQs

Overview

Customizable Autoimmune Models: Compliant, Fast, Publication-Ready

Cyagen accelerates therapeutic discovery with gene-edited models (CIA, EAE, TLR/DBA), offering end-to-end support from design to delivery. Meet deadlines with 12-week TurboKnockout® timelines and pre-validated datasets for peer review or FDA submissions.

Explore Ready-to-Use Mouse Models

Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.

You Might Be Also Interested In

MouseAtlas Model Library

Search and access curated genetically engineered mouse strains

Autoimmune & Inflammation CRO Platform

Advancing autoimmune drug discovery with models and efficacy data.

Oncology CRO Platform

End-to-end preclinical oncology support from models to IND data

Rodent Breeding

Scalable colony expansion with full genotyping support

Rodent Phenotyping

Full-spectrum analysis for rodents model

Cryopreservation & Recovery

Preserve and revive rodent strains on demand

Product

Model Selection Made Simple

Access Our Model Library >>

Base Strain

Catalog Number

Catalog Number	Name	Base Strain	Research Application
C001891	A129 (Ifnar1 KO)	129S2/SvPasCya	Investigating the pathogenesis and developing vaccines for arboviruses such as DENV, ZIKV, YFV, and CHIKV； Studying antiviral immune responses, interferon stimulation, and JAK-STAT signaling.
C001893	AG129	129S2/SvPasCya	Investigating the pathogenesis and developing vaccines for arboviruses such as DENV, ZIKV, YFV, and CHIKV; Studying antiviral immune responses, interferon stimulation, and JAK-STAT signaling.
C001694	B6-hCD3/hEPCAM	C57BL/6N;6JCya	Development and Evaluation of CD3/EPCAM-Targeted Drugs; Tumor Immunotherapy Research; Immunosuppressive Therapy Research for Autoimmune Diseases.
C001896	B6-huC3*R102G	C57BL/6JCya	Preclinical research on C3-targeted drugs; Research on Immune-related diseases caused by uncontrolled activation of the complement system (such as age-related macular degeneration (AMD)); Research in immunotherapy, oncology, etc.
C001898	B6;D1-htau/hTNF	C57BL/6J;DBA/1Cya	Research on Alzheimer's disease (AD); Research on frontotemporal dementia (FTD); Research on rheumatoid arthritis (RA); Research on TNF-α signaling pathway; Research on other neurodegenerative diseases or autoimmune diseases.
C001811	B6-huIL13/huTSLP	C57BL/6NCya	Screening, development, and pre-clinical evaluation of IL13/TSLP-targeted drugs; Mechanism research and development of treatment methods for allergic diseases, inflammations, and autoimmune diseases.
C001809	B6-hTSLP	C57BL/6NCya	TSLP-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of allergic and inflammatory diseases.
C001919	B6-huCFB/hMASP2	C57BL/6Cya	Screening, development, and evaluation of CFB/MASP2-targeted drugs; Research on the pathological mechanisms and treatment methods of immune-related diseases such as age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and systemic lupus erythematosus (SLE); Research on infectious diseases.
C001797	BALB/c-hIL13	BALB/cAnCya	IL13-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of allergic and inflammatory diseases; Research on parasitic infections and fibrotic diseases.
C001897	B6-hCD3/hCD19/hBCMA	C57BL/6NCya	Elucidation of the molecular mechanisms of T cell activation and antigen recognition; Development and evaluation of immunotherapies for autoimmune diseases; Research on B cell development and function; Mechanism and therapeutic research on autoimmune diseases (e.g., systemic lupus erythematosus, SLE, rheumatoid arthritis, RA) and B cell malignancies.

Items: 1 to 10 of 114

...

FAQs

Citation Database

Molecular Therapy: Methods & Clinical Development, March, 2025

Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing

【Other】

Gut, February, 2025

E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression

【Other】

Cell Death & Disease, February, 2025

Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage

【Other】

Molecular Therapy, February, 2025

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

【Other】

Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.